Literature DB >> 20151347

Management of dyspnea in patients with chronic obstructive pulmonary disease.

Amy P Abernethy1, Hope E Uronis, Jane L Wheeler, David C Currow.   

Abstract

A progressive and debilitating illness, chronic obstructive pulmonary disease (COPD) has major worldwide impact. In addition to the care for underlying causes of disease, COPD treatment involves palliative intervention to address associated symptoms; in later stages of disease, when the underlying disease has been maximally treated, symptom management assumes primacy as the goal of care. Dyspnea is the most distressing symptom experienced by COPD patients. When dyspnea cannot be relieved by traditional COPD management strategies (i.e., "refractory dyspnea"), the goal of care shifts from prolonged survival to minimized symptoms, improved function, and enhanced quality of life. Numerous pharmacologic and non-pharmacologic interventions are available to achieve these goals, but supporting evidence is variable. This review summarizes options for managing refractory dyspnea in COPD patients, referring to the available evidence and highlighting areas for further investigation. Topics include oxygen, opioids, psychotropic drugs, inhaled frusemide, Heliox28, nutrition, psychosocial support, and breathing techniques.

Entities:  

Mesh:

Year:  2009        PMID: 20151347     DOI: 10.1007/s10354-009-0727-z

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  66 in total

1.  The ventilatory effects of the head-down position in pulmonary emphysema.

Authors:  A L BARACH; G J BECK
Journal:  Am J Med       Date:  1954-01       Impact factor: 4.965

Review 2.  A systematic review of the use of opioids in the management of dyspnoea.

Authors:  A-L Jennings; A N Davies; J P T Higgins; J S R Gibbs; K E Broadley
Journal:  Thorax       Date:  2002-11       Impact factor: 9.139

Review 3.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

Review 4.  The neuropharmacology of respiratory control.

Authors:  R A Mueller; D B Lundberg; G R Breese; J Hedner; T Hedner; J Jonason
Journal:  Pharmacol Rev       Date:  1982-09       Impact factor: 25.468

5.  Postural relief of dyspnea in severe chronic obstructive pulmonary disease.

Authors:  J T Sharp; W S Drutz; T Moisan; J Foster; W Machnach
Journal:  Am Rev Respir Dis       Date:  1980-08

6.  Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease.

Authors:  G C Man; K Hsu; B J Sproule
Journal:  Chest       Date:  1986-12       Impact factor: 9.410

7.  Pursed lips breathing training using ear oximetry.

Authors:  B L Tiep; M Burns; D Kao; R Madison; J Herrera
Journal:  Chest       Date:  1986-08       Impact factor: 9.410

8.  Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial.

Authors:  M C Steiner; R L Barton; S J Singh; M D L Morgan
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

9.  Effects of alprazolam on respiratory drive, anxiety, and dyspnea in chronic airflow obstruction: a case study.

Authors:  J G Greene; F Pucino; J D Carlson; M Storsved; G L Strommen
Journal:  Pharmacotherapy       Date:  1989       Impact factor: 4.705

10.  Living with severe chronic obstructive pulmonary disease (COPD): perceptions of patients and their carers. An interpretative phenomenological analysis.

Authors:  D A Seamark; S D Blake; C J Seamark; D M Halpin
Journal:  Palliat Med       Date:  2004-10       Impact factor: 4.762

View more
  1 in total

1.  Caring for the older person with chronic obstructive pulmonary disease.

Authors:  Terri R Fried; Carlos A Vaz Fragoso; Michael W Rabow
Journal:  JAMA       Date:  2012-09-26       Impact factor: 56.272

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.